Arch Biopartners Price to Free Cash Flow Ratio 2021-2024 | ACHFF

Arch Biopartners price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as

Arch Biopartners Price to Free Cash Flow Ratio 2021-2024 | ACHFF

Arch Biopartners price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$77.5B
Zoetis (ZTS)$65.6B
Daiichi Sankyo, - (DSNKY)$46.1B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$32B
Sandoz Group AG (SDZNY)$25.2B
Summit Therapeutics (SMMT)$19.6B
Merck (MKKGY)$16.6B
Shionogi (SGIOY)$14.4B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.5B
Corcept Therapeutics (CORT)$7.4B
Madrigal Pharmaceuticals (MDGL)$7.3B
Stevanato Group S.p.A (STVN)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Procaps Group, S.A (PROCF)$3.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B